PLUG $7.49 -2.1569%
AMC.L $1.70 1.4948%
CDL.L $0.59 2.2609%
8031.HK $0.20 -0.5%
ESEM.L $31.01 0.7064%
0Y9S.L $120.64 -0.5581%
0274.HK $0.13 3.9062%
1189.HK $0.05 0%
AKW.PA $14.34 0.7022%
ECOZ $34.26 0%
TFI $46.47 -0.3539%
CPRT $81.24 0.8191%
ALIMM.BR $0.09 0%
DBGR $31.36 0%
EGLX $0.52 -1.6571%
KPG.NZ $0.91 0%
SVE.L $7.50 -5.0633%
JGLD $14.26 0%
DBAW $29.24 0.0062%
CASP.L $6.15 1.6529%
LHC $10.60 0.7605%
VETS $38.62 0%
IKNA $7.04 -2.7624%
1046.HK $0.28 -3.4483%
SRZN $0.55 -0.5045%
SFYX $11.17 -0.6228%
VCXAW $0.09 0.1116%
FTSL $45.04 0.0333%
MLTBM.PA $3.04 0%
SNX.L $106.50 2.4038%
CVSG.L $2 192.00 1.0138%
PARD3.SA $20.25 0%
HSCSW $0.15 -25.6122%
DWACU $15.81 4.6327%
WCC-PA $27.04 0.6701%
LYB $88.87 0.1127%
EWH $19.84 -2.001%
TFII $107.29 1.0359%
8121.HK $0.20 6.2827%
3331.HK $20.50 3.9554%
UJB $61.78 -0.206%
0QFK.L $0.61 -5%
MEG $35.06 -2.1763%
AMAR3.SA $0.66 -5.7143%
CLDL $6.20 -2.9733%
FIH.L $260.00 -3.7037%
TRYP.L $5.98 -0.8707%
VIDI $22.65 -0.9832%
ALUS $9.50 0%
FISI $15.91 0.0314%
EXPL.PA $93.00 0%
NTES $85.21 -3.6033%
0322.HK $13.24 -1.3413%
0QLQ.L $229.28 2.1259%
SHFT $17.83 5.8178%
SCHR $50.70 -0.3735%
EVT $21.77 -0.7159%
LYL $0.50 -35.5985%
HETA3.SA $96.00 0%
IBST.L $165.10 -1.1969%
MRAD $13.72 -0.9607%
0JZM.L $103.17 0%
PMF $9.83 -0.6481%
0936.HK $0.40 0%
RAMMU $10.68 0%
NRG $32.16 3.6108%
NDSN $215.42 -0.3792%
DATSW $0.05 1.6%
LYFT $8.25 -1.9619%
QDT.PA $17.48 -0.7946%
0Y4Q.L $228.34 2.6247%
PVAC $30.66 0%
1200.HK $0.81 -1.2195%
OFED $18.53 -1.0678%
IUMF.L $790.88 0.8287%
0LVK.L $113.40 -0.7309%
TGRW $24.88 -0.3113%
GENX.PA $9.70 0%
NTCO3.SA $13.09 1.3158%
IGG.L $706.50 -2.8198%
TYMN.L $255.50 0.9881%
BGSC.L $140.60 0%
ALCHI.PA $2.08 -0.9524%
PAY.L $427.50 -0.4657%
CEBR3.SA $12.60 0%
RISN $22.62 -0.1844%
HBRN.IR $1.60 0%
FSM $3.47 0.1445%
RKH.L $13.20 -5.7143%
SSTK $52.29 -0.6555%
RUSG.L $307.37 -0.1332%
SGAMU $0.00 0%
2113.HK $0.18 4.65116%
SPKAU $10.25 0%
1745.HK $0.70 1.4493%
EEA.PA $6.77 -2.0535%
IDTL.L $3.92 0.1404%
0IBC.L $95.83 1.4396%
UEVM $41.98 -1.2235%
ZYT.L $99.00 -1.4925%
Eng
Логотип
Eng
Лого

Redx Pharma Plc REDX.L

$33.50

+$1.03 (3.08%)
На 18:02, 12 мая 2023

Ранг: 3

Ранг - это оценка кредитоспособности корпорации.

Ключевые показатели

  • Marketcap

    108846078.00000000

  • week52high

    70.00

  • week52low

    26.50

  • Revenue

    18690000

  • P/E TTM

    -535

  • Beta

    -0.27557200

  • EPS

    -0.06000000

  • Last Dividend

    0.00000000

  • Next Earnings Date

    23 июн 2022 г. в 02:00

Описание компании

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company also develops RXC004, a porcupine inhibitor that is in Phase II clinical trial for targeted therapy of Wnt-ligand driven cancer; and RXC007, an oral selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor for the treatment of fibrotic diseases. In addition, it develops gastrointestinal targeted ROCK inhibitor to treat crohn's disease-associated fibrosis; discoidin domain receptors (DDRs) inhibitor for the treatment of multiple fibrotic conditions; and RXC006, a porcupine inhibitor targeting fibrotic diseases, including idiopathic pulmonary fibrosis. The company has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase pathway. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.

Свежие комментарии

Оставьте свой голос

Анонимное голосование

Будет ли рост российского рынка к концу года?

  • Да

    87%

  • Нет

    12%

Проголосовал 8 человек